PROfiling Based Endometrial Cancer Adjuvant Therapy

This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.

Trial Details

NCT ID
NCT05179447
Phase
NA
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Vaginal brachytherapy
  • External beam radiotherapy
  • Observation
  • Chemoradiation therapy
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667
  • Jinan, Shandong, China|36.66833,116.99722
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Beijing, China|39.9075,116.39723
  • Changsha, China|28.19874,112.97087

Key Eligibility Criteria

  • Surgery consisting of a total abdominal or laparoscopic hysterectomy, bilateral salpingectomy, pelvic lymphadenectomy or sentinel lymph node mappin…
  • Histologically confirmed endometrioid type endometrial carcinoma, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage I, with o…
  • Stage I A, grade 3 Stage I B, grade 1 or 2 Stage I B, grade 3 Stage II
  • World Health Organization (WHO)-performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →